Status and phase
Conditions
Treatments
About
Primary objective: Compare Pegasys RGT overall response rate (i.e., HBeAg seroconversion rate) with Pegasys mono historical response rate at week 72 (48 week treatment with 24 week follow up)
Secondary objective :
The changes of HBsAg titer
The rate of combined HBeAg seroconversion and HBV DNA < 300 copies/mL
The rate of serum HBV DNA < 300 copies/mL ⅳ. The rate of ALT normalization
Full description
After 12w treatment of Pegasys, depends on results of quantitative HBsAg test, Patients will be allocated to one of three groups.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
200 participants in 3 patient groups
Loading...
Central trial contact
Kwansik Lee, professor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal